Back to search

Peptide record

TPDB92081

BMAP-27 Antibacterial Anticancer Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92081
BMAP-27
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GRFKRFRKKFKKLFKKLSPVIPLLHL-NH2
Physicochemical Analysis
C158H262N44O28
ANDCEQMTWY
K
3226.10
12.73
11
0
11
+10
3.80
-0.365
101.15
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
0
Q
1
G
1
H
1
I
5
L
7
K
0
M
4
F
2
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 5 K: 7 M: 0 F: 4 P: 2 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
26
C158H262N44O28
3226.10
12.73
+10
3.80
-0.365
Amidation
L
Linear
Free
Antimicrobial
Cathelicidin
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 4.2 µM
Anticancer
4.2 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 5.3 µM
Anticancer
5.3 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2019